Lilly Cares ® Foundation Patient Assistance Program
Helping patients with financial need receive their prescribed Eli Lilly and Company (Lilly) medications at no cost.
Lilly Cares Foundation, Inc. (Lilly Cares) is a nonprofit charitable organization that provides prescribed Lilly medications for free for up to 12 months to qualifying U.S. patients. Over the past 20 years, Lilly Cares has helped more than one million patients with financial need receive medicines donated by Lilly.
- Terms of Use
- Privacy Statement
- Accessibility Statement
- Sitemap
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
You may also report negative side effects to The Lilly Answers Center (TLAC) at 1-800-LillyRx (1-800-545-5979).
This site is intended for U.S. residents age 18 and over only. Models used for illustrative purposes only. Not actual patients or healthcare providers.
PP-AP-US-0428 02/2023 ©Lilly USA, LLC 2023. All rights reserved.
All Lilly product names mentioned herein are either trademarks or registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, sialis shop or affiliates.
Lotus acquires Cialis® (Tadalafil) in Taiwan from Lilly
Lotus Pharmaceuticals (1795:TT), a multinational pharmaceutical company, today announced that its Board of Directors has approved to acquire the trademark, marketing authorization, and manufacturing know-how of Tadalafil 2.5mg, 5mg, 10mg and 20mg under the brand name of Cialis® in Taiwan for US$57.5 million from Eli Lilly and Company ("Lilly"). Immediately upon closing the transaction, the Company will take over the Cialis® business. The completion of this transaction is subject to customary closing conditions.
Tadalafil is indicated for the treatment of erectile dysfunction and benign prostatic hyperplasia, and Cialis® is positioned as the top 2 brand product for erectile dysfunction treatment with high brand loyalty. According to IQVIA data, the total sales of Cialis® in Taiwan for the last 12 months as of December 31, 2021 were approximately US$15.7 million. The Company believes the majority of Cialis sales are driven by drugstore channel.
The overall pharmaceutical market in Taiwan reached around US$8.0 billion in 2021, a 4% growth compared to the previous year. Among all the 3 distribution channels including hospitals and clinics, the drugstores channel accounted for 13.6% of the whole market in 2021 and was the only segment delivering over a 10% annual growth for the past 3 consecutive years. By adding the leading brand product into the portfolio, the Company expects it will expand its drugstore coverage from 1,500 to 2,500 by the year of 2025 and further accelerate the growth of its existing OTC portfolio.
Petar Vazharov, Chief Executive Officer of Lotus, said: "Brand acquisitions are important pillar in Lotus growth strategy since 2016 with Mercilon for Korean market being the first deal, followed by Aclasta and Evista for selective markets in Asia. The acquisition of a leading lifestyle brand as Cialis ® supports our strategy to gain more critical mass in Taiwan pharmaceutical market and enhances our penetration into the high growth drug store channel. It will also create greater scale and diversity across our portfolio and sales channels."
At Lilly, we want everyone to have access to the medicines they need.
We are committed to helping you understand how your health insurance situation affects the price you pay at the pharmacy counter — and we want to make sure you are aware of any special programs that could save you money.
This site shows the list price of our medicines and the amount you are likely to actually pay based on your insurance situation. For those who don’t have insurance, there are programs available to help people who qualify obtain the Lilly medicines they need at a lower cost or no cost.
- Terms of Use
- Privacy Statement
- Accessibility Statement
- Sitemap
To speak to customer support:
Call (800) 545-5979
This site is intended for US residents aged 18 or older.
PP-LU-US-0475 12/2022 © Lilly USA, LLC 2022. All rights reserved.
Baqsimi ® , Basaglar ® , Cyramza ® , Emgality ® , Erbitux ® , Humalog ® , Mounjaro ® , Olumiant ® , Reyvow ® , Taltz ® , Trulicity ® , Verzenio ® , and Lilly Cares ® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Companion in Care™, Olumiant Together™, Taltz Together™, and Verzenio Continuous Care™ are trademarks of Eli Lilly and Company.
Jardiance ® is a registered trademark of Boehringer Ingelheim International GmbH and is used under license.
